The association of enhanced HIV susceptibility with α4β7+CD4+T cells availability encouraged the investigation of targeting α4β7 with humanized anti-α4β7 monoclonal antibodies (mAbs) on SIV/HIV infection. This evidence concerns the gene CD4 and HIV infectious disease.